# Deal and market benchmarks: multiples, upfronts and IPO comps in the US and Europe
In 2019, Novartis paid roughly $9.7 billion to acquire Medicines Company for a single cardiovascular drug (inclisiran), a price that worked out to about 24 times the peak sales analysts modeled. Two years earlier, a profitable orthopedics maker might have changed hands at 4 times revenue. Same broad sector, wildly different math. This lesson gives you the benchmarks to tell the difference and read a deal or listing the way a sector analyst does.
Biotech and medtech look similar from the outside but are valued on opposite logic.
Medtech (medical devices, diagnostics, tools) is usually profitable, has recurring revenue, and trades on earnings multiples. Think of it like an industrial business with a regulatory moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition →.
Biotech (drug developers) is frequently pre-revenue, burns cash for years, and trades on the
So you need two toolkits.
For profitable medtech, the two workhorse multiples are:
These are broad ranges from public trading comparables, not precise figures, and they move with interest rates:
The single biggest driver of where a company sits is organic revenue growth rate and gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition →. A device grower compounding at 15% with 70% gross margins earns a premium multiple; a 3% grower does not.
A profitable diagnostics company has:
EV = 8.0 + 1.0 = $9.0 billion
If a peer with similar growth trades at 6x revenue, the market is arguably valuing this company at a discount, or pricing in slower growth or margin risk. That gap is where the analysis begins, not ends.
Drug developers rarely sell outright early. They license or partner assets. The structure matters more than the headline.
A typical licensing deal has three parts:
1. Upfront payment: cash paid at signing. This is the only guaranteed money.
2. Milestones: payments triggered by hitting clinical, regulatory (e.g. FDA approval), or sales targets. These are contingent and may never be paid.
3. Royalties: a percentage of future net sales.
Press releases love to trumpet the "biobucks" total (upfront + all milestones). That number is close to fiction because most milestones are far off and probabilistic.
The metric that reveals conviction is the upfront as a percentage of total deal value.
FDA = US Food and Drug Administration; EMA = European Medicines Agency. Regulatory milestones typically reference approval from these bodies.
A deal is announced as "up to $1.2 billion." The upfront is $150 million, with $1,050 million in milestones.
Upfront ratio = 150 / 1,200 = 12.5%
That tells you this is almost certainly an early-stage asset where the buyer is spreading risk. Compare that to a deal where the upfront is $600 million of a $1.2 billion total (50%): that signals a de-risked, likely late-stage asset, or a bidding war.
Always ask: *how much cash actually changes hands on day one?* For a cash-strapped biotech, a large upfront can be worth more than a huge but distant milestone stack.
For deal data and trends, the Nature Reviews Drug Discovery deal-making coverage and industry trackers are useful free starting points, and the FDA's drug approvals database lets you verify what actually cleared.
🎬 [VIDEO: "How Biotech Licensing Deals Work" - youtube.com - a clear walkthrough of upfronts, milestones and royalties in pharma partnerships]
Here is where fluency pays off. Comparable assets often trade at different valuations depending on where they list.
The Nasdaq (US) is by far the deepest biotech capital market. It has:
European listings (Euronext in Paris/Amsterdam, the London Stock Exchange (LSE), Germany's Deutsche Börse, Sweden's Nasdaq Stockholm) tend to have:
A pre-revenue oncology company with the same pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → will often achieve a higher valuation and larger raise on Nasdaq than on a European exchange (a widely observed pattern, not a fixed number). This is why many European biotechs (for example, several from the UK, France, and the Netherlands) have chosen to list on Nasdaq or dual-list, chasing valuation and liquidity.
Medtech is less lopsided. Profitable device makers with real cash flow are valued more consistently across regions because generalist investors can price earnings anywhere. The divergence is sharpest for story-driven, pre-revenue biotech.
Biotech IPO activity is intensely cyclical. The 2020 to 2021 window saw record Nasdaq biotech IPO volume; 2022 to 2023 saw a sharp freeze as interest rates rose. When you read any IPO comp, anchor it to *when* the deal priced. A multiple from a hot window is not a fair benchmark for a cold one.
Knowledge check
1. Why can't a standard earnings multiple be used to value a typical early-stage biotech company?
2. A medtech acquirer computes Enterprise Value as market capitalization plus net debt. What does this measure conceptually represent?
3. A profitable medical device company and a pre-revenue drug developer are in the same broad healthcare sector yet are valued using opposite logic. What best explains this distinction?
4. Select ALL correct answers about EV/EBITDA and EV/Revenue as valuation tools for medtech.
Select all the correct answers.
5. Select ALL correct answers explaining why a single cardiovascular drug could be acquired at roughly 24 times peak sales while a profitable orthopedics maker traded at about 4 times revenue.
Select all the correct answers.
When you look at a transaction or listing, run this quick mental checklist:
1. Is it medtech or biotech? Picks the toolkit (earnings multiple vs risk-adjusted asset value).
2. For medtech: what is the EV/Revenue and EV/EBITDAEBITDAEBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating profitability before financing and accounting decisions, used to compare core performance across firms.View full definition → versus growth-matched peers? A high multiple needs high growth to justify it.
3. For a biotech deal: what is the upfront ratio? Low ratio = early and speculative; high ratio = de-risked or competitive.
4. For a listing: US or Europe, and in what IPO window? Adjust expectations for the deeper US specialist pool.
A European Phase 2 immunology biotech signs a deal "worth up to €800 million" with $80 million upfront (ratio = 10%, clearly early-stage), then files to list on Nasdaq rather than Euronext. Both moves point the same way: the company is early, needs cash and validation, and is reaching for the deepest capital pool. None of that is a red flag. It is a rational response to how these markets are priced.
*All figures are broad estimates as of early 2026 for illustration, not investment advice. Verify current comparables against primary sources before use.*